What is Lyndra Therapeutics?
Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra Therapeutics is at the forefront of pharmaceutical innovation. The company is dedicated to developing advanced drug delivery systems, aiming to improve patient adherence and therapeutic outcomes through its proprietary long-acting oral dosage forms. This approach addresses critical unmet needs in chronic disease management by offering convenient and effective treatment options. The company's focus on novel manufacturing processes positions it as a key player in the evolving landscape of pharmaceutical technology.
How much funding has Lyndra Therapeutics raised?
Lyndra Therapeutics has raised a total of $239.5M across 4 funding rounds:
Series A
$23M
Series B
$55M
Series C
$60.5M
Series E
$101M
Series A (2018): $23M with participation from Polaris Partners
Series B (2019): $55M, investors not publicly disclosed
Series C (2021): $60.5M supported by Yipinhong Pharmaceutical Co., AIG Global Investment Group, Polaris Partners, Limitless Ventures, and Invus
Series E (2023): $101M featuring Sun Pharma, Sarissa Capital Acquisition, and Polaris Partners
Key Investors in Lyndra Therapeutics
Sun Pharma
Sun Pharma is a major specialty generic pharmaceutical company headquartered in Mumbai, India, focusing on the manufacturing and distribution of pharmaceutical formulations and active pharmaceutical ingredients.
Sarissa Capital Acquisition
Sarissa Capital Acquisition Corp. is a Cayman Islands-based entity formed for business combinations, indicating a strategic interest in mergers, acquisitions, or similar corporate activities within the pharmaceutical or biotech sectors.
Polaris Partners
Polaris Partners is a venture capital firm with a specialization in backing transformational companies within the biotech and healthcare sectors, providing strategic advice and resources for growth.
What's next for Lyndra Therapeutics?
The recent major strategic investment of $101M positions Lyndra Therapeutics for accelerated growth and the scaling of its innovative platform. This capital infusion is expected to fuel further research and development, expand manufacturing capabilities, and support clinical trial progression. The company's trajectory suggests a move towards commercialization and broader market penetration, leveraging its unique technology to address significant healthcare challenges. Strategic partnerships and further financing rounds may follow as Lyndra Therapeutics solidifies its market presence and advances its pipeline.
See full Lyndra Therapeutics company page
